Pittcon addresses synthetic psychedelics crisis; Boston 2025 to advance collaboration

Pittcon 2025 in Boston will connect industry experts to combat the synthetic psychedelic threat, enhancing testing protocols and public health initiatives.

Pharma is rethinking how it interacts with patients after Eli Lilly ripped up the playbook

(This story is from our new Health Tech newsletter. If you’d like to sign up, just click here.) More pharma companies are considering taking a

May 17, 2024

Amgen presents late-breaking Phase 2 olpasiran data at ESC 2023

Amgen today announced data from the final analysis of the Phase 2 OCEAN(a)-DOSE study of olpasiran, a small interfering RNA (siRNA) during the Late-Breaking Science Session

September 1, 2023

Shareholders approve the sale of Evolva AG to Lallemand Inc. Swiss subsidiary at extraordinary general meeting – Biotech Investments

Evolva Holding SA / Key word(s): AGMEGMShareholders approve the sale of Evolva AG to Lallemand Inc. Swiss subsidiary at extraordinary general meeting21.12.2023 / 17:45 CET/CEST

December 22, 2023

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.